It is not recommended for use in children between the ages of six months and three years, unless there is a compelling need.Clobazam is also available as an oral suspension in the UK, under the trade name of Tapclob.Please do not hesitate to inform your doctor or nurse regarding your feelings and how your mood or fatigue is impacting your quality of life and ability to function. ativan, xanax, valium etc) are often used to treat anxiety.
Other antiepileptic drugs may therefore be preferred for the long-term management of epilepsy.
Furthermore, benzodiazepines have the drawback, particularly after long-term use, of causing rebound seizures upon abrupt or over-rapid discontinuation of therapy forming part of the benzodiazepine withdrawal syndrome.
In the United Kingdom clobazam (Frisium) is approved for short-term (2–4 weeks) relief of acute anxiety in patients who have not responded to other drugs, with or without insomnia and without uncontrolled clinical depression.
It is also approved for adjunctive therapy for epilepsy in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs.
xanax, ativan, valium etc) because they do not have the same type of addictive potential.
Some antidepressants may be used to treat hot flashes and menopausal symptoms As with any treatment there is considerable individual variability in patient's response to these agents - some folks are helped readily, others are not; some have bad side effects and others don't.
Withdrawal from clobazam or other benzodiazepines after regular use often leads to withdrawal symptoms which are similar to those seen during alcohol and barbiturate withdrawal.
The higher the dose and the longer the drug is taken for, the greater the risk of experiencing unpleasant withdrawal symptoms.
Clobazam should be used with great care in patients with the following disorders: In December 2013 the FDA added warnings to the label for clobazam, that it can cause serious skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, especially in the first 8 weeks of treatment.
Overdose and intoxication with benzodiazepine, including ONFI, may lead to CNS depression, associated with drowsiness, confusion and lethargy, possibly progressing to ataxia, respiratory depression, hypotension and rarely coma or death.
Based on this assessment, different treatment options may be recommended.